Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib and Copanlisib in FGFR-positive Solid Tumors
NCT03517956Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of rogaratinib in solid tumor and urothelial carcinoma (UC), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent adverse events up to 32 months, Incidence of Dose-limiting toxicities and 1 more. Started Jul 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03517956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517956.